奧賽康(002755.SZ):子公司鹽酸帕洛諾司瓊注射液通過仿製藥一致性評價
格隆匯3月15日丨奧賽康(002755.SZ)公佈,公司的全資子公司江蘇奧賽康藥業有限公司(以下簡稱“子公司”)於近日收到國家藥監局核准簽發的鹽酸帕洛諾司瓊注射液《藥品補充申請批准通知書》,批准該藥品通過仿製藥質量和療效一致性評價。
帕洛諾司瓊為親和力較強的5-HT3受體選擇性拮抗劑,對其它受體無親和力或親和力較低。帕洛諾司瓊由美國Helsinn公司研發,於2003年首次在美國上市,隨後在德國、英國和日本等國家上市。2018年,鹽酸帕洛諾司瓊注射液進口獲NMPA批准,用於預防高度致吐化療引起的急性惡心、嘔吐;中度致吐化療引起的急性和延遲性惡心、嘔吐;手術後24小時內的噁心嘔吐。
噁心嘔吐是腫瘤患者在化療過程最常見的不良反應,如果出現反覆、持續的噁心嘔吐,不僅會對患者造成心理和生理上的不良影響,還會導致化療無法正常進行,影響療效。鹽酸帕洛諾司瓊是新一代5-HT3受體拮抗劑,與5-HT3受體親和力是其他拮抗劑的100倍左右,半衰期顯著延長達40h,具有劑量小、療效好、作用時間長和不良反應輕微等特點。此外,鹽酸帕洛諾司瓊通過與糖皮質激素聯用,可顯著提高5-HT3受體拮抗劑的療效,該聯用方案已成為急性化療藥物所致噁心、嘔吐的標準治療方案。PDB數據庫顯示2019年中國樣本醫院銷售額達6.4億元,市場潛力大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.